Gleave M - Search Results

1

Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours.

So AI, Bowden M, Gleave M. So AI, et al. Among authors: gleave m. BJU Int. 2004 Apr;93(6):845-50. doi: 10.1111/j.1464-410X.2003.04726.x. BJU Int. 2004. PMID: 15050003

2

[Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].

Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD. Gleave M, et al. Prog Urol. 1996 Jun;6(3):375-85. Prog Urol. 1996. PMID: 8763692 French.

3

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Sato N, et al. Among authors: gleave me. J Steroid Biochem Mol Biol. 1996 May;58(2):139-46. doi: 10.1016/0960-0760(96)00018-0. J Steroid Biochem Mol Biol. 1996. PMID: 8809195

4

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. Sato N, et al. Among authors: gleave me. Cancer Res. 1997 Apr 15;57(8):1584-9. Cancer Res. 1997. PMID: 9108464

5

Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.

Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1997 May;157(5):1727-30. J Urol. 1997. PMID: 9112514

6

Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.

Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L. Gleave ME, et al. J Cell Biochem. 1998 Jun 1;69(3):271-81. J Cell Biochem. 1998. PMID: 9581866

7

Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.

Nickerson T, Miyake H, Gleave ME, Pollak M. Nickerson T, et al. Among authors: gleave me. Cancer Res. 1999 Jul 15;59(14):3392-5. Cancer Res. 1999. PMID: 10416600

8

Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.

Miyake H, Tolcher A, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 1999 Aug 15;59(16):4030-4. Cancer Res. 1999. PMID: 10463603

9

Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Gleave M, et al. Clin Cancer Res. 1999 Oct;5(10):2891-8. Clin Cancer Res. 1999. PMID: 10537358

10

Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.

Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Gleave ME, et al. Urology. 1999 Dec;54(6A Suppl):36-46. doi: 10.1016/s0090-4295(99)00453-7. Urology. 1999. PMID: 10606283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

692 results

Search Page

Filters